What is the pathophysiology of anticholinergic drug effects on blood pressure?

Anticholinergic Effects on Blood Pressure: Pathophysiology

Anticholinergic drugs paradoxically increase blood pressure through central nervous system mechanisms, where blocking acetylcholine in specific brainstem regions (particularly the C1 area of the rostral ventrolateral medulla) disinhibits sympathetic outflow, leading to elevated sympathetic nerve activity and subsequent hypertension.

Central Cholinergic Regulation of Blood Pressure

The pathophysiology centers on the brain's acetylcholine system as a critical regulator of cardiovascular homeostasis. Under normal conditions, central cholinergic pathways exert tonic control over blood pressure through muscarinic receptors in key brainstem cardiovascular centers 1, 2.

Key Mechanisms:

Central Sympathetic Disinhibition:

• The C1 area of the rostral ventrolateral medulla contains reticulospinal cardiovascular neurons that directly excite preganglionic sympathetic neurons
• These neurons are normally modulated by cholinergic input acting on M2 muscarinic receptors
• When anticholinergic drugs block these M2 receptors, they remove inhibitory cholinergic tone, resulting in increased sympathetic nerve activity 2
• This leads to elevated arterial pressure and heart rate through enhanced sympathetic outflow to the cardiovascular system

Peripheral Manifestations:

• The increased central sympathetic drive translates peripherally to:
  • Elevated peripheral vascular resistance
  • Increased cardiac output
  • Enhanced catecholamine release
  • Impaired baroreceptor reflex responses 1

Clinical Cardiovascular Consequences

Recent large-scale evidence demonstrates substantial cardiovascular harm from anticholinergic burden 3. In a population-based cohort of over 500,000 adults followed for 14 years, cumulative anticholinergic exposure showed a dose-dependent relationship with cardiovascular events:

• Low exposure (1-89 DDDs annually): HR 1.16 (95% CI: 1.13-1.20)
• Moderate exposure (90-364 DDDs annually): HR 1.31 (95% CI: 1.28-1.34)
• High exposure (≥365 DDDs annually): HR 1.71 (95% CI: 1.67-1.76)

The highest exposure group showed particularly elevated risks for:

• Heart failure: HR 2.70 (95% CI: 2.57-2.84)
• Arrhythmias: HR 2.17 (95% CI: 2.08-2.27)
• Myocardial infarction: HR 1.46 (95% CI: 1.37-1.55)

Clinical Implications and Guideline Considerations

The 2019 AGS Beers Criteria explicitly warns about anticholinergic drugs in older adults, noting their propensity to cause multiple adverse effects including cardiovascular complications 4. The guidelines emphasize that anticholinergic burden should be minimized whenever possible, particularly in vulnerable populations.

Important Caveats:

Postural Hypotension vs. Sustained Hypertension:

• While anticholinergics increase sympathetic tone centrally, some agents (particularly tricyclic antidepressants with anticholinergic properties) can cause postural hypotension through peripheral alpha-adrenergic blockade 5
• This creates a complex picture where patients may have elevated supine blood pressure but orthostatic drops

Parasympathetic Withdrawal:

• Peripheral anticholinergic effects on the heart (blocking vagal tone) contribute to tachycardia but do not appear to be the primary driver of blood pressure elevation 6
• The central mechanisms predominate in determining overall blood pressure effects

Time-Dependent Effects:

• The cardiovascular risks appear cumulative, with time-updated exposure models showing stronger associations than baseline exposure alone 3
• This suggests ongoing anticholinergic burden progressively damages cardiovascular regulation

Practical Clinical Approach

When evaluating patients on anticholinergic medications, monitor for:

• Resting tachycardia (peripheral vagal blockade)
• Elevated blood pressure, particularly in supine position
• Impaired blood pressure variability and baroreceptor responses
• Signs of heart failure or arrhythmias with chronic exposure

Deprescribing anticholinergic medications should be prioritized in patients with cardiovascular disease or risk factors, as reducing anticholinergic burden can improve cardiovascular outcomes 3, 7.